Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Zipeng Lu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5694-1422; OpenAlex author ID A5039939828, A5101016997. Sources: OpenAlex.

Their work

Papers
58 (first author 8, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
153
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: 6 papers · 2018: 6 papers · 2019: 3 papers · 2020: 4 papers · 2021: 9 papers · 2022: 5 papers · 2023: 6 papers · 2024: 4 papers · 2025: 8 papers · 2026: 2 papers

Papers 50 of 58

  1. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  2. Long-term outcomes of upfront pancreatectomy with venous resection for pancreatic cancer: a single-center, retrospective analysis. Co-author DOI 10.1097/js9.0000000000003617↗
  3. Comparison of Radical Antegrade Modular Pancreatosplenectomy Versus Standard Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Mat… Co-author DOI 10.1002/wjs.12630↗
  4. Complications following upfront pancreatectomy with venous resection do not compromise adjuvant chemotherapy delivery and survival in pancreatic cancer. Co-author DOI 10.1007/s00423-025-03933-z↗
  5. Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Co-author DOI 10.1016/j.xcrm.2024.101927↗
  6. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Co-author DOI 10.1038/s41388-025-03530-w↗
  7. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-024-01358-7↗
  8. USP19 potentiates autophagic cell death via inhibiting mTOR pathway through deubiquitinating NEK9 in pancreatic cancer. Last author DOI 10.1038/s41418-024-01426-y↗
  9. Germline mutations and pancreatic cancer risk in chronic pancreatitis. Co-author DOI 10.1136/gutjnl-2024-334277↗
  10. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. Co-author DOI 10.1200/jco.24.00287↗
  11. High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance. Last author DOI 10.1007/s10495-023-01901-w↗
  12. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.03.005↗
  13. Efficiency evaluation of dual-energy CT to predict the postoperative early recurrence of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.09.012↗
  14. A Targeted Octahedral DNA Nanostructure Co-delivers siME3 and Doxorubicin to Enhance Collateral Lethality in ME2-Deficient Pancreatic Cancer. Co-author DOI 10.1021/acs.nanolett.4c05123↗
  15. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study. Co-author DOI 10.1002/cam4.5296↗
  16. Cancer-testis gene STK31 is regulated by methylation and promotes the development of pancreatic cancer. Co-author DOI 10.1002/cam4.5472↗
  17. Rim Enhancement and Peripancreatic Fat Stranding in Preoperative MDCT as Predictors for Occult Metastasis in PDAC Patients. Co-author DOI 10.1016/j.acra.2023.03.007↗
  18. Technical options in surgery for artery-involving pancreatic cancer: Invasion depth matters. Last author DOI 10.1016/j.sopen.2023.03.001↗
  19. Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/20552076231179007↗
  20. Establishment and validation of a nomogram based on coagulation parameters to predict the prognosis of pancreatic cancer. Co-author DOI 10.1186/s12885-023-10908-0↗
  21. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. Co-author DOI 10.1001/jamanetworkopen.2021.48721↗
  22. A histopathological study of artery wall involvement in pancreatic cancer surgery. Co-author DOI 10.1007/s00423-022-02689-0↗
  23. The distinct genetic features of pancreatic cancer in Chinese population. Co-author DOI 10.1016/j.ebiom.2022.103960↗
  24. Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing. Co-author DOI 10.1186/s12943-022-01636-3↗
  25. Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star. Co-author DOI 10.1186/s13578-022-00833-3↗
  26. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. First author DOI 10.1007/s00423-021-02080-5↗
  27. Survival prediction after upfront surgery in patients with pancreatic ductal adenocarcinoma: Radiomic, clinic-pathologic and body composition analysis. Co-author DOI 10.1016/j.pan.2021.02.009↗
  28. Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST… First author DOI 10.1016/j.pan.2021.05.300↗
  29. Metabolic detection and systems analyses of pancreatic ductal adenocarcinoma through machine learning, lipidomics, and multi-omics. Co-author DOI 10.1126/sciadv.abh2724↗
  30. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Co-author DOI 10.1186/s12943-021-01333-7↗
  31. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02063-w↗
  32. Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC. Co-author DOI 10.3389/fcell.2021.714718↗
  33. Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.744667↗
  34. CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.832315↗
  35. Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis. Co-author DOI 10.1007/s00268-019-05325-z↗
  36. CircRHOT1 mediated cell proliferation, apoptosis and invasion of pancreatic cancer cells by sponging miR-125a-3p. Co-author DOI 10.1111/jcmm.15572↗
  37. A novel antisense lncRNA NT5E promotes progression by modulating the expression of SYNCRIP and predicts a poor prognosis in pancreatic cancer. Co-author DOI 10.1111/jcmm.15718↗
  38. LncRNA KCNK15-AS1 inhibits pancreatic cancer progression by promoting the expression of its binding protein ACTR3B Co-author DOI 10.21203/rs.3.rs-55282/v1↗
  39. Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis. Co-author DOI 10.1002/cam4.2145↗
  40. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Co-author DOI 10.1016/j.prp.2019.152666↗
  41. LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/β-Catenin Signaling Pathway. Co-author DOI 10.1177/1533033819887962↗
  42. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Co-author DOI 10.1002/ijc.31173↗
  43. Long non-coding RNA lnc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3. Co-author DOI 10.1002/ijc.31657↗
  44. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Co-author DOI 10.1007/s11523-018-0578-x↗
  45. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. First author DOI 10.1016/j.gene.2018.06.037↗
  46. ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation. Co-author DOI 10.1159/000491915↗
  47. Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regul… Co-author DOI 10.1186/s12943-018-0761-9↗
  48. Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Co-author DOI 10.1016/j.biomaterials.2017.08.002↗
  49. Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. First author DOI 10.1016/j.canlet.2017.03.024↗
  50. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase reg… Co-author DOI 10.1186/s12943-017-0619-6↗

Closest collaborators

The 25 strongest of 153 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 39 shared papers, 2011–2026 · strength 4.31
  2. Yi Miao · 33 shared papers, 2011–2025 · strength 3.57
  3. Baobao Cai · 15 shared papers, 2013–2025 · strength 1.89
  4. Lingdi Yin · 10 shared papers, 2021–2025 · strength 1.63
  5. Jishu Wei · 13 shared papers, 2011–2025 · strength 1.43
  6. Junli Wu · 10 shared papers, 2011–2026 · strength 1.34
  7. Xumin Huang · 8 shared papers, 2020–2026 · strength 1.20
  8. Kuirong Jiang · 6 shared papers, 2018–2025 · strength 1.11
  9. Guangfu Wang · 6 shared papers, 2021–2025 · strength 1.10
  10. Min Tu · 9 shared papers, 2013–2026 · strength 1.09
  11. Wentao Gao · 10 shared papers, 2011–2026 · strength 1.04
  12. Pengfei Wu · 11 shared papers, 2013–2022 · strength 0.96
  13. Yi Miao · 7 shared papers, 2013–2025 · strength 0.88
  14. Kai Zhang · 5 shared papers, 2020–2025 · strength 0.85
  15. Hao Yuan · 9 shared papers, 2017–2022 · strength 0.84
  16. Shangnan Dai · 4 shared papers, 2021–2025 · strength 0.78
  17. Yunpeng Peng · 6 shared papers, 2014–2025 · strength 0.75
  18. Guodong Shi · 9 shared papers, 2017–2020 · strength 0.69
  19. Qun Chen · 6 shared papers, 2020–2022 · strength 0.69
  20. Kai Zhang · 4 shared papers, 2017–2026 · strength 0.62
  21. Qing Xu · 3 shared papers, 2021–2024 · strength 0.57
  22. Pengfei Wu · 3 shared papers, 2018–2026 · strength 0.54
  23. Kai Zhang · 4 shared papers, 2021–2022 · strength 0.51
  24. Pengfei Wu · 5 shared papers, 2019–2021 · strength 0.51
  25. Taoyue Yang · 4 shared papers, 2021–2022 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.